The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review
Authors:
- Wiktoria UlickaWUWiktoria Ulicka
- Patryk DudekPDPatryk Dudek
- Klaudia ŁuczakKŁKlaudia Łuczak
- Marcel ChudzikowskiMCMarcel Chudzikowski
- Agnieszka PawlikAPAgnieszka Pawlik
- Justyna PiętaJPJustyna Pięta
- Adrianna TabeauATAdrianna Tabeau
- Hanna SitarekHSHanna Sitarek
- Joanna PrusJPJoanna Prus
- Agata ProkopiukAPAgata Prokopiuk
Open Access
- 22 April 2025
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 59398
Abstract
Alzheimer’s disease (AD), often referred to as type 3 diabetes, is characterized by neuroinflammation, oxidative stress, mitochondrial dysfunction, and brain insulin resistance, leading to cognitive decline. GLP-1 receptor agonists, originally developed for type 2 diabetes, demonstrate neuroprotective properties that address these pathologies. They improve insulin sensitivity, reduce amyloid-beta deposition, tau hyperphosphorylation, and neuronal apoptosis while enhancing synaptic plasticity, autophagy, and neural stem cell proliferation. Studies highlight their potential as innovative AD therapies. However, further research is needed to confirm their efficacy and long-term safety in combating neurodegeneration.Keywords
This publication has 70 references indexed in Scilit:
- Neurotheranostics as personalized medicinesAdvanced Drug Delivery Reviews, 2019
- Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular TargetingNeuroscience Bulletin, 2019
- The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's diseaseThe Journal of Pathology, 2018
- Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's diseaseBiochemical and Biophysical Research Communications, 2018
- Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic RatsMolecular Neurobiology, 2017
- Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory ResponsesMolecular Neurobiology, 2017
- Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 miceBehavioural Brain Research, 2015
- In Vivo Seeding and Cross-Seeding of Localized AmyloidosisThe American Journal of Pathology, 2015
- Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 DiabetesArchives of Neurology, 2011
- Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and ironJournal of Neuroscience Research, 2003